Research output per year
Research output per year
Personal profile
External positions
University of South Alabama
Fingerprint
Dive into the research topics where Meera Varman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic
Podraza, L., Vasudevan, J., Hudson, C., Jayan, A. & Varman, M., Feb 2022, In: Journal of Community Health. 47, 1, p. 87-93 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
Olsson, S. E., Restrepo, J. A., Reina, J. C., Pitisuttithum, P., Ulied, A., Varman, M., Van Damme, P., Moreira, E. D., Ferris, D., Block, S., Bautista, O., Gallagher, N., McCauley, J. & Luxembourg, A., Dec 2020, In: Papillomavirus Research. 10, 100203.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention
Varman, M., Sharlin, C., Fernandez, C., Vasudevan, J. & Wichman, C., Jun 1 2018, In: Journal of Community Health. 43, 3, p. 455-458 4 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
Kovac, M., Kostanyan, L., Mesaros, N., Kuriyakose, S. & Varman, M., May 9 2018, In: Human Vaccines and Immunotherapeutics. 14, 8, p. 1977-1986 10 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial
The MMR-161 Study Group, Sep 11 2018, In: Vaccine. 36, 38, p. 5781-5788 8 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations